Study of PRG-N-01 for people with neurofibromatosis type 2
Part of Brain & nervous system, Cancer, Ear, nose & throat, Genetic & congenital clinical trials.
This trial tests a new medicine called PRG-N-01 for people with neurofibromatosis type 2 (NF2), a condition that causes tumors on nerves. The study aims to find the best dose and see if the medicine can shrink tumors or improve symptoms like hearing loss or pain, especially for those who cannot have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of NF2, either by genetic testing or clinical criteria.
- You have NF2-related tumors that are growing or causing symptoms, but you cannot have surgery because it would be too risky.
- You are generally able to care for yourself (ECOG score 0-1 or Karnofsky score 70 or higher).
- You have adequate organ function (blood, liver, kidney, heart, lungs) as determined by tests.
- You agree to use sunscreen during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at new medicines for people with NF2-related schwannomatosis (NF2-SWN), a condition that causes tumors on nerves. It first tracks the natural course of the disease and may later test experimental drugs to help shrink or control tumors.
This trial tests a drug called selumetinib (a pill) for people with NF2-related schwannomatosis, a condition that causes non-cancerous tumors to grow on nerves, especially near the ears. The goal is to see if the drug can shrink or stabilize these tumors and protect hearing.
This trial tests a combination of two investigational drugs for people with NF2-related tumors. The drugs target specific pathways to help shrink or slow growth of vestibular schwannomas and meningiomas.
This trial tests an oral drug called FCN-159 for people with NF2-related nerve sheath tumors that cannot be fully removed by surgery or have come back after surgery. It aims to see if the drug can shrink or slow the growth of these tumors.
This trial studies targeted medicines in people with neurofibromatosis type 2 (NF2) who have growing tumors on scans. The goal is to slow tumor growth and improve symptoms by testing different drug combinations in separate study groups.
This trial tests a new gene therapy that is injected directly into tumors caused by NF2. It aims to help people whose tumors have not responded to standard treatments.
Hear when a new Neurofibromatosis Type II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.